Stephen Staal

Stephen Staal, M.D.

Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832

About Stephen Staal

Dr. Staal’s professional career spans more than 35 years and includes conducting basic and applied cancer research, caring for patients, and organizing and administering a clinical cancer program. He has an interest in the molecular mechanisms that define cancer cells and how these can be exploited therapeutically. Clinically his interests are focused on experimental therapeutics, breast cancer, and clinical management to promote research and improve patient care.

Clinical Profile

Specialties
  • Cancer
Areas of Interest
  • Adult Brain Tumors
  • Breast cancer
  • Cancer – resources
  • Cancer treatment information
  • Lymphoma
  • Melanoma
  • Metastatic Brain Tumor

Publications

2010
Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.
Methods in molecular biology (Clifton, N.J.). 624:385-92 [DOI] 10.1007/978-1-60761-609-2_26. [PMID] 20217610.
2009
The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss Or Bust?
Journal of Clinical Oncology. 27:1545-1548

Grants

Aug 2022 ACTIVE
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via BRISTOL MYERS SQUIBB CO
Feb 2020 ACTIVE
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial assigning individualized Options for Treatment: The TAILORx Trial
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via BREAST CANCER RESEARCH FOU
Mar 2019 ACTIVE
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Sep 2015 – Sep 2020
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Role: Principal Investigator
Funding: ECOG-ACRIN CANCER RESEARCH GROUP via NATL INST OF HLTH NCI
Apr 2015 – Jul 2018
214 Fund – A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Role: Principal Investigator
Funding: AMGEN INC
Feb 2015 – Feb 2019
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
Role: Project Manager
Funding: SYNEOS HEALTH via STEMLINE THERAPEUTICS, INC
May 2013 – Nov 2017
A RANDOMIZED PHASE II STUDY OF MK-3475 VERSUS CHEMOTHEREAPY IN PATIENTS WITH ADVANCED MELANOMA
Role: Principal Investigator
Funding: Merck Sharp & Dohme
May 2013 – May 2016
A Randomized Phase II study of MK-3475 versus chemothereapy in Patients with Advanced Melanoma
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Apr 2012 – Apr 2020
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High Dose Interferon a-2b for Resected High Risk Melanoma
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP via NATL INST OF HLTH NCI
Apr 2010 – Apr 2019
A Phase III Clinical Trial comparing the combination of TC plus Bevacizumab to TC alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL via GENENTECH INC
May 2008 – May 2019
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial assigning individualized Options for Treatment: The TAILORx Trial
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP via NATL INST OF HLTH
Feb 2008 – Aug 2021
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival i
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL

Education

Fellowship – Oncology
1978 · Johns Hopkins University
Residency – Internal Medicine
1977 · Johns Hopkins University
Medical Degree
1972 · University of California, San Diego
Medical Degree
1972 · University of California, San Diego
Bachelor of Arts
1968 · University of California, Los Angeles

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
PO Box 100278
HEALTH SCIENCES CTR
GAINESVILLE FL 32610